Tag Archives: Biotech IPO

Enacted in April 2012, the Jumpstart Our Business Startups (JOBS) Act makes the pathway to capital formation more attainable for small biotechnology companies, clearing the way for American innovation and ingenuity by removing bureaucratic hurdles and red tape to speed cures and medical breakthroughs to patients. The JOBS Act reached a major milestone last week, with the 100th company going public under its provisions. On October 7th at the 13th Annual BIO Investor Forum, we Read More >

The 16th Annual BIO CEO & Investor Conference​ concluded with a lively Closing Plenary Session examining the current capital market for IPOs, where the industry has been and where it’s headed in 2014. The panel unanimously agreed: 2013 was the year of the IPO. In total, 56 healthcare companies priced an IPO; 43 of these were biotech companies. Last year was the strongest IPO year since 2000 and the second strongest in history with over $10 Read More >

Everyone knows that it’s been a knock-out year for the biotech sector in the public markets, which includes a large and well-performing IPO class. So far in 2013, 39 US-based companies have gone public, five European-based companies, and one Canadian company. Of these 45 IPOs, 42 companies have gone public on US stock exchanges. That’s over double the amount we saw in 2012. This year’s IPOs have also been successful at raising the amount of money Read More >